Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gonzalo Spera

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Epidemiology (Cambridge, Mass.)|May 18, 2018
The Authors RespondGonzalo Spera, Rodrigo Fresco, Helena Fung, et al.
The Oncologist|May 31, 2015
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical TrialsRodrigo Fresco, Gonzalo Spera, Carlos Meyer, et al.
Clinical Breast Cancer|March 10, 2019
Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced MalignancyCarlos Meyer, Pablo Millán, Valeria González, et al.
Biologics : Targets & Therapy|August 27, 2009
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancerEduardo Lasalvia-Prisco, Emilio Garcia-Giralt, Jesús Vázquez, et al.
The Oncologist|August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trialsAndrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
The Lancet. Oncology|September 1, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 studySara A Hurvitz, Aditya Bardia, Vanesa Quiroga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast CancerCristiano Ferrario, John Mackey, Karen A Gelmon, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Epidemiology (Cambridge, Mass.)|May 18, 2018
The Authors RespondGonzalo Spera, Rodrigo Fresco, Helena Fung, et al.
The Oncologist|May 31, 2015
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical TrialsRodrigo Fresco, Gonzalo Spera, Carlos Meyer, et al.
Clinical Breast Cancer|March 10, 2019
Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced MalignancyCarlos Meyer, Pablo Millán, Valeria González, et al.
Biologics : Targets & Therapy|August 27, 2009
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancerEduardo Lasalvia-Prisco, Emilio Garcia-Giralt, Jesús Vázquez, et al.
The Oncologist|August 21, 2025
Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trialsAndrea Blasco, Sara López-Tarruella, Ander Urruticoechea, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
The Lancet. Oncology|September 1, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 studySara A Hurvitz, Aditya Bardia, Vanesa Quiroga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast CancerCristiano Ferrario, John Mackey, Karen A Gelmon, et al.
Pageof 1